9LB Stock Overview
Through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 9LB from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Legend Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.80 |
| 52 Week High | US$55.50 |
| 52 Week Low | US$24.60 |
| Beta | 0.20 |
| 1 Month Change | -13.89% |
| 3 Month Change | -27.91% |
| 1 Year Change | -39.81% |
| 3 Year Change | -36.08% |
| 5 Year Change | n/a |
| Change since IPO | 3.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9LB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -11.4% | -0.3% | 0.8% |
| 1Y | -39.8% | -12.7% | 14.6% |
Return vs Industry: 9LB underperformed the German Biotechs industry which returned -12.3% over the past year.
Return vs Market: 9LB underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| 9LB volatility | |
|---|---|
| 9LB Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 9LB has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 9LB's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 2,700 | Ying Huang | www.legendbiotech.com |
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China.
Legend Biotech Corporation Fundamentals Summary
| 9LB fundamental statistics | |
|---|---|
| Market cap | €4.59b |
| Earnings (TTM) | -€195.66m |
| Revenue (TTM) | €653.21m |
7.0x
P/S Ratio-23.5x
P/E RatioIs 9LB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9LB income statement (TTM) | |
|---|---|
| Revenue | US$728.30m |
| Cost of Revenue | US$665.69m |
| Gross Profit | US$62.61m |
| Other Expenses | US$280.76m |
| Earnings | -US$218.15m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.18 |
| Gross Margin | 8.60% |
| Net Profit Margin | -29.95% |
| Debt/Equity Ratio | 30.0% |
How did 9LB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 08:57 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Legend Biotech Corporation is covered by 32 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Huidong Wang | Barclays |
| Konstantinos Biliouris | BMO Capital Markets Equity Research |